Celltrion (KRX:068270) secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers (PBMs), Pulse News reported Tuesday.
This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.
Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。